Rituximab in induction therapy for anti-neutrophil cytoplasmic antibody (ANCA) vasculitis

Clinical and Experimental Immunology

Volumn 164, Issue SUPPL. 1, 2011, Pages 27-30

  Niles, J ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

ANCA; ANCA associated vasculitis; Rituximab

Indexed keywords

CYCLOPHOSPHAMIDE; NEUTROPHIL CYTOPLASMIC ANTIBODY; RITUXIMAB; STEROID;

ANCA ASSOCIATED VASCULITIS; ANTIBODY TITER; ARTICLE; B LYMPHOCYTE; CELL ACTIVATION; CELLULAR IMMUNITY; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG TARGETING; DRUG WITHDRAWAL; HUMAN; HUMORAL IMMUNITY; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFLUENZA VACCINATION; INFUSION REACTION; LEUKOPENIA; LOW DRUG DOSE; NEUTROPENIA; NEUTROPHIL; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RECURRENT DISEASE; REMISSION; RHEUMATOID ARTHRITIS; T LYMPHOCYTE;

ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; FEMALE; HUMANS; IMMUNITY, CELLULAR; IMMUNOLOGIC FACTORS; MALE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 79953151276     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2011.04363.x     Document Type: Article

References (27)

1. Fauci AS, Wolff SM. Wegener's granulomatosis: studies in eighteen patients and a review of the literature. Medicine (Balt) 1973; 52:535-61.
2. Choi HK, Liu S, Merkel PA, Colditz GA, Niles JL. Diagnostic performance of antineutrophil cytoplasmic antibody tests for idiopathic vasculitides: metaanalysis with a focus on antimyeloperoxidase antibodies. J Rheumatol 2001; 28:1584-90.
3. Han WK, Choi HK, Roth RM, McCluskey RT, Niles JL. Serial ANCA titers: useful tool for prevention of relapses in ANCA-associated vasculitis. Kidney Int 2003; 63:1079-85.
4. Tervaert JW, van der Woude FJ, Fauci AS etal. Association between active Wegener's granulomatosis and anticytoplasmic antibodies. Arch Intern Med 1989; 149:2461-5.
5. Jayne DR, Gaskin G, Rasmussen N etal. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol 2007; 18:2180-8.
6. Falk RJ, Terrell RS, Charles LA, Jennette JC. Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc Natl Acad Sci USA 1990; 87:4115-9.
7. Rarok AA, Limburg PC, Kallenberg CG. Neutrophil-activating potential of antineutrophil cytoplasm autoantibodies. J Leukoc Biol 2003; 74:3-15.
8. Radford DJ, Savage CO, Nash GB. Treatment of rolling neutrophils with antineutrophil cytoplasmic antibodies causes conversion to firm integrin-mediated adhesion. Arthritis Rheum 2000; 43:1337-45.
9. Schreiber A, Xiao H, Jennette JC, Schneider W, Luft FC, Kettritz R. C5a receptor mediates neutrophil activation and ANCA-induced glomerulonephritis. J Am Soc Nephrol 2009; 20:289-98.
10. Kallenberg CG. Pathophysiology of ANCA-associated small vessel vasculitis. Curr Rheumatol Rep 2010; 12:399-405.
11. Xiao H, Heeringa P, Hu P etal. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest 2002; 110:955-63.
12. Schreiber A, Xiao H, Falk RJ, Jennette JC. Bone marrow-derived cells are sufficient and necessary targets to mediate glomerulonephritis and vasculitis induced by anti-myeloperoxidase antibodies. J Am Soc Nephrol 2006; 17:3355-64.
13. Xiao H, Heeringa P, Liu Z etal. The role of neutrophils in the induction of glomerulonephritis by anti-myeloperoxidase antibodies. Am J Pathol 2005; 167:39-45.
14. van der Kolk LE, Baars JW, Prins MH, van Oers MH. Rituximab treatment results in impaired secondary humoral immune responsiveness. Blood 2002; 100:2257-9.
15. Bingham CO III, Looney RJ, Deodhar A etal. Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial. Arthritis Rheum 2010; 62:64-74.
16. Keystone E, Fleischmann R, Emery P etal. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum 2007; 56:3896-908.
17. Popa C, Leandro MJ, Cambridge G, Edwards JC. Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 yrs. Rheumatology (Oxf) 2007; 46:626-30.
18. van Assen S, Holvast A, Benne CA etal. Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab. Arthritis Rheum 2010; 62:75-81.
19. Leandro MJ, Cambridge G, Ehrenstein MR, Edwards JC. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum 2006; 54:613-20.
20. van Vollenhoven RF, Emery P, Bingham CO III etal. Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials. J Rheumatol 2010; 37:558-67.
21. Kamar N, Mengelle C, Rostaing L. Incidence of JC-virus replication after rituximab therapy in solid-organ transplant patients. Am J Transplant 2009; 9:244-5.
22. Stone JH, Merkel PA, Spiera R etal. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010; 363:221-32.
23. Jones RB, Tervaert JW, Hauser T etal. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010; 363:211-20.
24. Fleischmann RM. Safety of biologic therapy in rheumatoid arthritis and other autoimmune diseases: focus on rituximab. Semin Arthritis Rheum 2009; 38:265-80.
25. Jones RB, Ferraro AJ, Chaudhry AN etal. A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2009; 60:2156-68.
26. Keogh KA, Ytterberg SR, Fervenza FC, Carlson KA, Schroeder DR, Specks U. Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. Am J Respir Crit Care Med 2006; 173:180-7.
27. Rhee EP, Laliberte KA, Niles JL. Rituximab as maintenance therapy for anti-neutrophil cytoplasmic antibody-associated vasculitis. Clin J Am Soc Nephrol 2010; 5:1394-400.